65,437 trials
Crohn's Disease · Ulcerative Colitis (Part 2 Only)
Primary: Descriptive Statistics of Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State (Part 1) — 20825679.963; 7821587.111; 12609504.125; 9377712.620…
Psoriatic Arthritis
Primary: Change in Heart Rate Variability (HRV) Measure — 13.38; -13.48 ms
Chronic Hepatitis C
Primary: Change in Serum HCV RNA Viral Titer From Baseline to 28 Days — -0.46; -0.11 log IU/ml
Peripheral Artery Disease · Femoropopliteal Artery Occlusion · Femoropopliteal Stenosis
Primary: Number of Participants With Unanticipated Device- or Drug-Related Serious Adverse Events at 60 Months Post Index Procedure. — 0; 0 Participants
Herpes Simplex
Primary: Number of Participants Positive and Negative for HSV-1 by SA201 HSV-1/2 PCR Test — 281; 54; 9; 1237 Participants
Breast Neoplasms
Primary: Insulin — -21.8; -17.7; -13.2; -1.1 percent change from baseline
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants Reporting Solicited Injection-Site and Systemic Reaction Following Vaccination With Either MenACYW Conjugate Vaccine or NIMENRIX® — 28; 31; 0; 1…
Persistent Atrial Fibrillation
Primary: Number of Participants With Freedom From Device/Procedure Related Major Adverse Events (MAEs) — 3; 126 Participants
Angina, Stable Chest Pain
Primary: Comparison of CCTA Alone to FFR-CT After CCTA — 90.97; 92.73; 22.86; 69.71 percent — p=1.00
Bone Infection · Joint Infection
Primary: The Frequency of Definite Failure of Infection Treatment. — 67; 74 Participants
Meningococcal Infections
Primary: Antibody Titers Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Before a Booster Dose of MenACYW…
Hemorrhoids · Postoperative Pain
Primary: Postoperative Pain on the Visual Analogue Scale (VAS) — 1.4; 3.1 units on a scale
Type 2 Diabetes Mellitus
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) Through the End of the Up-titration Period…
Inflammatory Bowel Diseases
Primary: Mucosal Impedance Values — 1139; 849; 891; 783 ohms